Argues that issues like misleading evidence, financial conflicts of interest, and the over-promotion of new drugs negatively impact cancer treatment and patient care. It critiques the reliance on surrogate endpoints over actual survival benefits in drug approvals, highlights the exorbitant cost of cancer drugs, and scrutinizes the design and interpretation of clinical trials. Prasad advocates for reforms in drug development, regulation, and research funding, emphasizing the need for impartiality and patient-centered outcomes. The author also offers advice for patients and medical trainees on navigating the complexities of cancer medicine.You can listen and download our episodes for free on more than 10 different platforms:https://linktr.ee/book_shelterGet the Book now from Amazon:https://www.amazon.com/-/es/Malignant-Policy-Evidence-People-Cancer/dp/1421437635?&linkCode=ll1&tag=cvthunderx-20&linkId=501e2673f8d94b2c8b505ec8d4ceeb63&language=en_US&ref_=as_li_ss_tlProduced by:https://www.podcaistudio.com/

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related